Is lupus anticoagulant testing with dilute Russell's viper venom clotting times reliable in the presence of inflammation?

C-reactive protein antiphospholipid antibodies dilute Russell’s viper venom inflammation lupus anticoagulant

Journal

Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 17 07 2024
accepted: 18 07 2024
medline: 18 9 2024
pubmed: 18 9 2024
entrez: 18 9 2024
Statut: epublish

Résumé

Testing for lupus anticoagulant (LA) is not recommended in case of inflammation as C-reactive protein (CRP) can interfere To study the effect of inflammation, as evidenced by increased CRP levels, on DRVV tests. First, a retrospective analysis (2013-2023) was performed: data on all LA workups were retrieved, and the association between CRP levels and DRVV screen, mix, and confirm clotting times was studied. Second, data on DRVV panels and CRP levels were extracted from 2 prospective studies involving intensive care unit patients to study the association between both variables. Third, CRP was added to normal pooled plasma at 6 relevant concentrations (up to 416 mg/L) to study the association between CRP itself and DRVV coagulation times. In the retrospective analysis, DRVV screen and confirm clotting times significantly increased as CRP increased (increase of 0.11 seconds and 0.03 seconds per 1 mg/L increase of CRP level, respectively). In the prospective analysis, only DRVV screen was prolonged with high CRP levels (increase of 0.06 seconds for a 1 mg/L increase in CRP level); DRVV screen/confirm ratio was also increased with high CRP levels. LA testing should be performed with much caution in the presence of inflammation as it may be associated with prolongation of both activated partial thromboplastin time and DRVV clotting times.

Sections du résumé

Background UNASSIGNED
Testing for lupus anticoagulant (LA) is not recommended in case of inflammation as C-reactive protein (CRP) can interfere
Objectives UNASSIGNED
To study the effect of inflammation, as evidenced by increased CRP levels, on DRVV tests.
Methods UNASSIGNED
First, a retrospective analysis (2013-2023) was performed: data on all LA workups were retrieved, and the association between CRP levels and DRVV screen, mix, and confirm clotting times was studied. Second, data on DRVV panels and CRP levels were extracted from 2 prospective studies involving intensive care unit patients to study the association between both variables. Third, CRP was added to normal pooled plasma at 6 relevant concentrations (up to 416 mg/L) to study the association between CRP itself and DRVV coagulation times.
Results UNASSIGNED
In the retrospective analysis, DRVV screen and confirm clotting times significantly increased as CRP increased (increase of 0.11 seconds and 0.03 seconds per 1 mg/L increase of CRP level, respectively). In the prospective analysis, only DRVV screen was prolonged with high CRP levels (increase of 0.06 seconds for a 1 mg/L increase in CRP level); DRVV screen/confirm ratio was also increased with high CRP levels.
Conclusion UNASSIGNED
LA testing should be performed with much caution in the presence of inflammation as it may be associated with prolongation of both activated partial thromboplastin time and DRVV clotting times.

Identifiants

pubmed: 39290988
doi: 10.1016/j.rpth.2024.102536
pii: S2475-0379(24)00231-0
pmc: PMC11406037
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102536

Informations de copyright

© 2024 The Author(s).

Auteurs

Michael Hardy (M)

Institut de Recherche Expérimentale et Clinique - Pôle Mont, Université Catholique de Louvain, Louvain-la-Neuve, Belgium.
Department of Laboratory Medicine, CHU UCL Namur, Yvoir, Belgium.
Anesthesiology Department, CHU UCL Namur, Yvoir, Belgium.
Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Namur, Belgium.

Emilie Catry (E)

Institut de Recherche Expérimentale et Clinique - Pôle Mont, Université Catholique de Louvain, Louvain-la-Neuve, Belgium.
Department of Laboratory Medicine, CHU UCL Namur, Yvoir, Belgium.

Marie Pouplard (M)

Department of Laboratory Medicine, CHU UCL Namur, Yvoir, Belgium.

Thomas Lecompte (T)

Department of Pharmacy, Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Université de Namur, Namur, Belgium.
Faculté de Médecine de Nancy, Université de Lorraine, Nancy, France.
Division of Vascular Medicine, Centre hospitalier régional universitaire Nancy, Nancy, France.

François Mullier (F)

Institut de Recherche Expérimentale et Clinique - Pôle Mont, Université Catholique de Louvain, Louvain-la-Neuve, Belgium.
Department of Laboratory Medicine, CHU UCL Namur, Yvoir, Belgium.
Namur Thrombosis and Hemostasis Center (NTHC), Namur Research Institute for Life Sciences (NARILIS), Namur, Belgium.

Classifications MeSH